000892409 001__ 892409
000892409 005__ 20210628150956.0
000892409 0247_ $$2doi$$a10.1111/epi.16906
000892409 0247_ $$2Handle$$a2128/27935
000892409 0247_ $$2altmetric$$aaltmetric:105348648
000892409 0247_ $$2pmid$$a33951195
000892409 0247_ $$2WOS$$aWOS:000647207200001
000892409 037__ $$aFZJ-2021-02067
000892409 082__ $$a610
000892409 1001_ $$0P:(DE-HGF)0$$aHe, Hailan$$b0
000892409 245__ $$aThe molecular and phenotypic spectrum of CLCN4-related epilepsy
000892409 260__ $$aOxford [u.a.]$$bWiley-Blackwell$$c2021
000892409 3367_ $$2DRIVER$$aarticle
000892409 3367_ $$2DataCite$$aOutput Types/Journal article
000892409 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1623333107_9171
000892409 3367_ $$2BibTeX$$aARTICLE
000892409 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000892409 3367_ $$00$$2EndNote$$aJournal Article
000892409 520__ $$aObjectiveThis study was undertaken to expand the phenotypic and genetic spectrum of CLCN4-related epilepsy and to investigate genotype–phenotype correlations.MethodsWe systematically reviewed the phenotypic and genetic spectrum of newly diagnosed and previously reported patients with CLCN4-related epilepsy. Three novel variants identified in four patients reported in this study were evaluated through in silico prediction and functional analysis by Western blot, immunofluorescence, and electrophysiological measurements.ResultsEpilepsy was diagnosed in 54.55% (24/44) of individuals with CLCN4-related disorders and was drug-resistant in most cases. Of 24 patients, 15 had epileptic encephalopathy and four died at an early age; 69.57% of patients had seizure onset within the first year of life. Myoclonic seizures are the most common seizure type, and 56.25% of patients presented multiple seizure types. Notably, seizure outcome was favorable in individuals with only one seizure type. All patients showed intellectual disability, which was severe in 65.22% of patients. Additional common features included language delay, behavioral disorders, and dysmorphic features. Five patients benefitted from treatment with lamotrigine. Most variants, which were mainly missense (79.17%), were inherited (70.83%). Whereas frameshift, intragenic deletion, or inherited variants were associated with milder phenotypes, missense or de novo variants led to more severe phenotypes. All evaluated CLCN4 variants resulted in loss of function with reduced ClC-4 currents. Nonetheless, genotype–phenotype relationships for CLCN4-related epilepsy are not straightforward, as phenotypic variability was observed in recurrent variants and within single families.SignificancePathogenic CLCN4 variants contribute significantly to the genetic etiology of epilepsy. The phenotypic spectrum of CLCN4-related epilepsy includes drug-resistant seizures, cognitive and language impairment, behavioral disorders, and congenital anomalies. Notably, the mutation type and the number of seizure types correlate with the severity of the phenotype, suggesting its use for clinical prognosis. Lamotrigine can be considered a therapeutic option.
000892409 536__ $$0G:(DE-HGF)POF4-524$$a524 - Molecular and Cellular Information Processing (POF4-524)$$cPOF4-524$$fPOF IV$$x0
000892409 7001_ $$0P:(DE-Juel1)156375$$aGuzman, Raul$$b1$$ufzj
000892409 7001_ $$0P:(DE-HGF)0$$aCao, Dezhi$$b2
000892409 7001_ $$0P:(DE-HGF)0$$aSierra-Marquez, Juan$$b3
000892409 7001_ $$0P:(DE-HGF)0$$aYin, Fei$$b4
000892409 7001_ $$0P:(DE-Juel1)136837$$aFahlke, Christoph$$b5$$ufzj
000892409 7001_ $$0P:(DE-HGF)0$$aPeng, Jing$$b6$$eCorresponding author
000892409 7001_ $$0P:(DE-HGF)0$$aStauber, Tobias$$b7
000892409 773__ $$0PERI:(DE-600)2002194-X$$a10.1111/epi.16906$$n6$$p1401-1415$$tEpilepsia$$v62$$x0013-9580$$y2021
000892409 8564_ $$uhttps://juser.fz-juelich.de/record/892409/files/epi.16906.pdf$$yOpenAccess
000892409 909CO $$ooai:juser.fz-juelich.de:892409$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000892409 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)156375$$aForschungszentrum Jülich$$b1$$kFZJ
000892409 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-HGF)0$$aForschungszentrum Jülich$$b3$$kFZJ
000892409 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)136837$$aForschungszentrum Jülich$$b5$$kFZJ
000892409 9130_ $$0G:(DE-HGF)POF3-551$$1G:(DE-HGF)POF3-550$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lBioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences$$vFunctional Macromolecules and Complexes$$x0
000892409 9131_ $$0G:(DE-HGF)POF4-524$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vMolecular and Cellular Information Processing$$x0
000892409 9141_ $$y2021
000892409 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-02-04
000892409 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000892409 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-02-04
000892409 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-04
000892409 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-02-04
000892409 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEPILEPSIA : 2019$$d2021-02-04
000892409 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000892409 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-02-04$$wger
000892409 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-02-04
000892409 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000892409 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-02-04
000892409 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000892409 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-02-04
000892409 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEPILEPSIA : 2019$$d2021-02-04
000892409 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-02-04
000892409 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-02-04
000892409 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-02-04
000892409 920__ $$lyes
000892409 9201_ $$0I:(DE-Juel1)IBI-1-20200312$$kIBI-1$$lMolekular- und Zellphysiologie$$x0
000892409 980__ $$ajournal
000892409 980__ $$aVDB
000892409 980__ $$aUNRESTRICTED
000892409 980__ $$aI:(DE-Juel1)IBI-1-20200312
000892409 9801_ $$aFullTexts